AUTOIMMUNE DISEASE

THE UNMET NEED

 
 
badge-3mAmericans.png

Around three million Americans have type 1 diabetes.1

badge-14-9bn.png

The annual healthcare costs associated with type 1 diabetes are $14.9 billion in the USA alone.2

badge-4-5pcGlobalPop.png

Up to 4.5% of the global population is diagnosed with an autoimmune disease.3

 
 

 
 

THE PIONEERING SOLUTION

 
 

DiaVacs


Diavacs is a clinical stage biotechnology company developing a novel immunotherapy to re-induce tolerance in type 1 diabetes and a multitude of other autoimmune diseases.


DiaVacs’ treatment offers local antigen-specific immunosuppression, halting the pathogenic autoimmune response, without compromising the body’s immune system. It also complements emerging regenerative approaches by protecting newly created beta cells from autoimmune attack.

 
 

References

1. JDRF. Type 1 Diabetes. Facts 2011: http://www2.jdrf.org/site/DocServer/KW-T1D_Factsheet.pdf?docID=1024 Accessed April 2018. 2. Dall TM et al. Popul Health Manag 2009; 12(2): 103–110 3. Hayter SM and Cook MC. Autoimmune Rev 2012; 11(10): 754–765.